Clinical trial
Candesartan in the Prevention of Relapsing Atrial Fibrillation
NCT00130975 · Asker & Baerum Hospital, Other · Completed
Key facts
| NCT number | NCT00130975 |
|---|---|
| Title | Candesartan in the Prevention of Relapsing Atrial Fibrillation |
| Lead sponsor | Asker & Baerum Hospital, Other |
| Collaborators | Helse Ost Ullevaal University Hospital AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation |
| Intervention type | Drug |
| Interventions | Candesartan |
| Enrollment | 200 |
| Start date | Apr 1, 2001 |
| Completion | Sep 1, 2005 |
| First posted | Aug 17, 2005 |
| Last update posted | Jan 4, 2007 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: